title: Neoadjuvant chemotherapy after liver transplantation for hepatocellular carcinoma.
authors.affiliation: Institute of Liver Studies, King's College Hospital, London, United Kingdom.
authors.forename: P M
authors.initials: PM
authors.lastname: Rizzi
authors.forename: S D
authors.initials: SD
authors.lastname: Ryder
authors.forename: J K
authors.initials: JK
authors.lastname: Ramage
authors.forename: E
authors.initials: E
authors.lastname: Gane
authors.forename: J
authors.initials: J
authors.lastname: Karani
authors.forename: N
authors.initials: N
authors.lastname: Heaton
authors.forename: B
authors.initials: B
authors.lastname: Portmann
authors.forename: K C
authors.initials: KC
authors.lastname: Tan
authors.forename: R
authors.initials: R
authors.lastname: Williams
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007165:Immunosuppression Therapy; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D016031:Liver Transplantation / Q000401:mortality; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors; D000509:alpha-Fetoproteins / Q000032:analysis
chemical_list: D000509:alpha-Fetoproteins; D004317:Doxorubicin